A Phase I-II Trial of Everolimus and Sorafenib in Patients With Recurrent High-Grade Gliomas
Latest Information Update: 03 Jun 2022
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Adverse reactions; Therapeutic Use
- 14 Jul 2021 Status changed from active, no longer recruiting to completed.
- 09 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 05 Aug 2020 Planned End Date changed from 31 Dec 2021 to 30 Jun 2022.